Ciprofloxacin

Researchers are comparing two anesthesia drugs, Ciprofol and Propofol, in children aged 3 to 11 years undergoing adenotonsillectomy or adenoidectomy. The study evaluates how these drugs perform under two types of monitoring called IoC1 and IoC2, aiming to provide evidence about Ciprofols safety and effectiveness in pediatric anesthesia. Children in this trial are randomly assigned to one of two groups. One group receives Ciprofol during anesthesia induction and maintenance at specified doses, while the other group receives Propofol with its own dosing schedule. Throughout surgery, vital signs and monitoring parameters IoC1 and IoC2 are continuously observed. Participants will be assessed during and after anesthesia using various measures including an Induction Compliance Checklist, time to loss of consciousness, sedation and pain-stress levels, heart rate, blood pressure, anesthetic dosage, recovery time, anesthetist satisfaction, and monitoring for adverse events. Follow-up includes observations up to 24 hours post-procedure to understand recovery and possible side effects.

This research aims to evaluate whether ciprofol, a new intravenous anesthetic, can improve blood pressure stability during surgery in elderly patients who have been using renin-angiotensin system inhibitors long-term. These patients often face increased risk of low blood pressure during surgery, which can lead to serious complications like heart and kidney injury or higher mortality. Ciprofol has shown promise in previous studies for better maintaining blood pressure compared to propofol, but more evidence is needed. The study randomly assigns patients undergoing elective abdominal surgery lasting over two hours to receive either ciprofol or propofol for anesthesia induction and maintenance. Both drugs are given intravenously during surgery. The trial is designed as a triple-blind, randomized controlled trial to compare how each anesthetic affects perioperative blood pressure and related outcomes. Participants will be monitored from the start to the end of surgery for blood pressure levels, use of blood pressure medications, anesthesia success, and any adverse events. Additional measures include heart and brain oxygen levels and recovery times. Postoperative complications will be tracked for up to three months. This thorough monitoring aims to understand the safety and hemodynamic effects of ciprofol in this vulnerable group.

Researchers are investigating the effective dose of ciprofol, a new intravenous anesthetic similar to propofol but with fewer side effects, for children aged 1 to 12 years undergoing elective surgeries that require laryngeal mask airway LMA insertion during general anesthesia. The study aims to find the 95% effective dose ED95 of ciprofol when combined with a fixed dose of fentanyl 1 gkg to optimize LMA insertion without the use of neuromuscular blockers. This phase 4, single-blind trial enrolls pediatric patients divided into three age groups toddlers, preschoolers, and school-age children. Participants receive a predetermined intravenous bolus dose of ciprofol administered over one minute along with fentanyl. The initial ciprofol dose is 0.35 mgkg and adjusted by a biased-coin design based on the success or failure of LMA insertion, which is attempted 90 seconds after drug administration. The study monitors insertion success defined by the absence of jaw tightness or movement and uses isotonic regression with bootstrap resampling to estimate the effective dose for each age group. During the trial, participants are assessed for vital signs including mean arterial pressure, heart rate, and Bispectral Index from before induction to one minute after LMA insertion. Adverse events within five minutes, as well as emergence delirium scores in the recovery area, are also recorded. The study evaluates the primary outcome of ED95 for ciprofol and monitors secondary outcomes related to safety and anesthesia quality throughout the procedure and recovery period.